SS
VTGN icon

SBI Securities’s VistaGen Therapeutics VTGN Stock Holding History

SBI Securities’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65 Buy
289
+1
+0.3% +$1 ﹤0.01% 3612
2026
Q1 		$165 Hold
288
– – ﹤0.01% 3284
2025
Q4 		$191 Sell
288
-2
-0.7% -$7 ﹤0.01% 3227
2025
Q3 		$1.03K Buy
290
+2
+0.7% +$6 ﹤0.01% 2684
2025
Q2 		$576 Buy
288
+2
+0.7% +$5 ﹤0.01% 2909
2025
Q1 		$715 Hold
286
– – ﹤0.01% 2735
2024
Q4 		$844 Buy
+286
New +$805 ﹤0.01% 2686

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return

SBI Securities's VTGN Position: Q2 2026 in Review

SBI Securities increased its VistaGen Therapeutics (VTGN) stake by 0.35% in Q2 2026, buying an estimated $1 and bringing the position to 289 shares worth $65. The position accounts for ﹤0.01% of the portfolio, ranked #3612.

SBI Securities first reported a position in VTGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.03K in Q3 2025. 26 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • SBI Securities held 289 shares of VistaGen Therapeutics worth $65 as of Q2 2026.
  • SBI Securities bought 1 VistaGen Therapeutics share in Q2 2026, an estimated $1.
  • VistaGen Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3612 holding.
  • SBI Securities first reported a position in VistaGen Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's VistaGen Therapeutics position peaked at $1.03K in Q3 2025.
  • 26 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.